Day: August 16, 2022

VANCOUVER, British Columbia, Aug. 15, 2022 (GLOBE NEWSWIRE) — Pure Gold Mining Inc. (TSX-V:PGM, LSE:PUR) (“PureGold” or the “Company”), today provided an operational update and outlook as well as financial results for the second quarter of 2022. PureGold owns and operates the PureGold Mine near Red Lake, Ontario. So far during the third quarter, both costs and revenues are trending in the right direction on a sequential quarterly basis, due to the groundwork laid in the first and second quarters. As a result, the Company forecasts the Mine to deliver positive site-level cash flow in the third quarter, achieving a previously stated objective. Moreover, a team of multidisciplinary consultants led by SRK Consulting (Canada) Inc. (“SRK”) remains on track to complete an updated Life of Mine plan and a new Pre-Feasibility Study (“PFS”)...

DENVER, Aug. 15, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported financial results for the six months ended June 30, 2022. Financial Results for the Six Months Ended June 30, 2022 Net Loss: The net loss attributable to common stockholders was $8.09 million, from operations, or a basic and diluted loss per share of $(1.31). For the same period in 2021, loss from operations was $13.53 million, or a basic and diluted loss per share attributable to common stockholders of ($3.04) and which included a $4.2 million impairment charge and a loss of $103,285 from discontinued operations, Cash Position: The Company had $324,146 in cash...

TORONTO, Aug. 15, 2022 (GLOBE NEWSWIRE) — Medivolve Inc. (“Medivolve” or the “Company”) (NEO: MEDV; OTC: COPRF; FRA: 4NC), a healthcare technology company that seeks to improve the US healthcare system by leveraging a bespoke telehealth platform, clinical diagnostic network, and data driven AI to improve patient care, today announced financial results for the second quarter ended June 30, 2022. “Medivolve delivered another strong quarter of financial results, achieving a 72% increase in revenue growth compared the same year to date period in 2021,” said David Preiner, CEO of Medivolve. “We are extremely proud to have improved the quality of patient care with our Increased Patient Access program. In addition, this program helped the company achieve gross profit of $10,542,208 representing 483% growth compared to...